{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  
  "substances": [
    {
      "id": "ibogaine_001",
      "name": "Ibogaine",
      "aliases": ["Iboga", "Tabernanthe iboga"],
      "classification": {
        "primary": "atypical_psychedelic",
        "secondary": ["indole_alkaloid"],
        "mechanism": "multi_receptor_interaction",
        "receptorAffinity": {
          "kappa_opioid": "high",
          "mu_opioid": "moderate",
          "NMDA": "moderate",
          "sigma_2": "moderate",
          "5HT2A": "low"
        },
        "note": "Not a classic serotonergic psychedelic; doesn't heavily rely on 5-HT2A receptor"
      },
      "metabolites": [
        {
          "name": "noribogaine",
          "active": true,
          "conversionSite": "liver",
          "conversionEnzyme": "CYP2D6",
          "conversionSpeed": "moderate",
          "halfLife": {"value": 48, "unit": "hours", "note": "Significantly longer than ibogaine"},
          "psychoactiveProperties": true,
          "clinicalSignificance": "Effects can persist for up to 48 hours"
        }
      ],
      "prevalenceData": {
        "traditionalUse": {
          "regions": ["Gabon", "Cameroon", "West Central Africa"],
          "tradition": "Bwiti spiritual and medicinal practices",
          "citations": ["cherian_2024", "knuijver_2022"]
        },
        "sustainabilityConcerns": {
          "issue": "Increasing demand leading to overharvesting",
          "risks": ["exploitation_of_indigenous_communities", "environmental_degradation"],
          "citations": ["cherian_2024"]
        },
        "fatalitiesReviewed": {
          "value": 19,
          "context": "Ibogaine-related fatalities in literature review",
          "withPreexistingHeartConditions": 6,
          "citations": ["cherian_2024"]
        }
      },
      "dosing": {
        "therapeutic": {
          "typical": {"min": 25, "max": 42, "unit": "mg/kg"},
          "route": "oral",
          "context": "For therapeutic purposes (e.g., addiction treatment)",
          "citations": ["gomez-escolar_2024"]
        },
        "administration": {
          "forms": ["powder", "extract", "hydrochloride"],
          "route": "oral_primary",
          "note": "Oral administration is standard; other routes should only occur in strictly controlled clinical settings"
        },
        "weightDependence": true,
        "note": "Dosing is highly individual and weight-dependent"
      },
      "pharmacokinetics": {
        "absorption": {
          "route": "oral",
          "formulations": ["powder", "extract", "hydrochloride"]
        },
        "onset": {"min": 30, "max": 120, "unit": "minutes"},
        "peak": {"min": 2, "max": 4, "unit": "hours"},
        "duration": {"min": 4, "max": 8, "unit": "hours"},
        "metaboliteDuration": {"min": 24, "max": 48, "unit": "hours", "metabolite": "noribogaine"},
        "metabolism": {
          "primary": "Hepatic via CYP2D6 to noribogaine",
          "geneticVariability": true,
          "note": "Poor metabolizers at higher risk"
        },
        "elimination": "renal",
        "pharmacokineticProfile": "complex"
      },
      "toleranceDevelopment": {
        "rate": "unknown",
        "crossTolerance": "unknown",
        "note": "Limited research on tolerance patterns"
      },
      "addictionPotential": "low",
      "physiologicalDependence": "none reported",
      "psychologicalDependence": "minimal"
    }
  ],

  "riskFactors": [
    {
      "id": "rf_ibogaine_cardiovascular_001",
      "name": "Pre-existing Cardiovascular Conditions",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "description": "Heart conditions, QT prolongation, arrhythmias - CRITICAL for ibogaine",
      "severity": "critical",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "absolute",
          "riskLevel": "critical",
          "specificConditions": [
            {
              "condition": "cardiac_arrhythmias",
              "severity": "critical",
              "contraindicationType": "absolute"
            },
            {
              "condition": "long_qt_syndrome",
              "severity": "critical",
              "contraindicationType": "absolute"
            },
            {
              "condition": "prolonged_baseline_qt",
              "severity": "critical",
              "contraindicationType": "absolute",
              "mechanism": "Can be induced by medications (antibiotics, antidepressants)"
            },
            {
              "condition": "hERG_mutations",
              "severity": "critical",
              "contraindicationType": "absolute",
              "association": "Long QT syndrome"
            },
            {
              "condition": "coronary_artery_sclerosis",
              "severity": "critical",
              "riskType": "increased_fatality_risk"
            },
            {
              "condition": "myocardial_infarct",
              "severity": "critical",
              "riskType": "increased_fatality_risk"
            },
            {
              "condition": "cardiac_hypertrophy",
              "severity": "critical",
              "riskType": "increased_fatality_risk"
            },
            {
              "condition": "dilated_cardiomyopathy",
              "severity": "critical",
              "riskType": "increased_fatality_risk"
            }
          ],
          "physiologicalEffects": {
            "qtProlongation": {
              "severity": "critical",
              "mechanism": "Direct cardiac effect",
              "averageIncrease": {"value": 95, "unit": "ms", "range": {"min": 29, "max": 146}},
              "clinicallySignificantThreshold": {"value": 500, "unit": "ms"},
              "prevalenceAboveThreshold": {
                "value": 50,
                "unit": "percent",
                "context": "Of participants in safety study"
              },
              "consequence": "Life-threatening Torsade de pointes (TdP) arrhythmia",
              "citations": ["knuijver_2022", "glue_2016", "koenig_2015"]
            },
            "bradycardia": {
              "severity": "high",
              "description": "Slow heart rate",
              "riskWindow": "Within first 72 hours",
              "association": "Sudden death risk"
            }
          },
          "fatalityData": {
            "reviewedDeaths": 19,
            "withPreexistingHeartConditions": 6,
            "citation": "cherian_2024"
          },
          "requiredMonitoring": [
            "Continuous ECG monitoring during administration",
            "Post-administration ECG monitoring",
            "Medical supervision essential",
            "Baseline ECG required"
          ],
          "citations": ["cherian_2024", "koenig_2015", "glue_2016", "rocha_2023", "baumeister_2015"],
          "evidenceQuality": "strong"
        }
      ],
      "clinicalSignificance": "Ibogaine has unique and severe cardiovascular risks not seen with classical psychedelics",
      "monitoringRecommendations": [
        "Pre-screening ECG mandatory",
        "Continuous ECG monitoring during session",
        "Post-session monitoring for 72 hours minimum",
        "Electrolyte panel before administration",
        "Medical emergency response capability required"
      ]
    },
    {
      "id": "rf_ibogaine_electrolytes_001",
      "name": "Electrolyte Imbalances",
      "category": "physiological",
      "subcategory": "metabolic",
      "description": "Abnormal potassium or magnesium levels",
      "severity": "critical",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "absolute_if_uncorrected",
          "riskLevel": "critical",
          "specificImbalances": [
            {
              "imbalance": "hypokalemia",
              "description": "Low potassium",
              "severity": "critical",
              "mechanism": "Increases cardiac risk with ibogaine",
              "contraindicationType": "absolute_if_uncorrected"
            },
            {
              "imbalance": "hypomagnesemia",
              "description": "Low magnesium",
              "severity": "critical",
              "mechanism": "Increases cardiac risk with ibogaine",
              "contraindicationType": "absolute_if_uncorrected"
            }
          ],
          "consequences": [
            "Elevated risk of cardiac arrhythmias",
            "Increased QT prolongation",
            "Higher fatality risk"
          ],
          "requiredScreening": [
            "Baseline electrolyte panel",
            "Correction of imbalances before administration",
            "Monitoring during session"
          ],
          "citations": ["koenig_2015"],
          "evidenceQuality": "moderate_to_strong"
        }
      ]
    },
    {
      "id": "rf_ibogaine_genetic_metabolism_001",
      "name": "CYP2D6 Genetic Variations",
      "category": "physiological",
      "subcategory": "pharmacogenetics",
      "description": "Genetic variations affecting ibogaine metabolism",
      "severity": "high",
      "specificGeneticFactors": [
        {
          "gene": "CYP2D6",
          "relevantSubstances": ["ibogaine_001"],
          "variants": [
            {
              "type": "poor_metabolizer",
              "frequency": "5-10% of population",
              "effect": "Impaired metabolism of ibogaine",
              "consequence": "Higher plasma concentrations, increased toxicity risk",
              "interaction": "Methadone inhibits CYP2D6, creating similar risk"
            }
          ],
          "citations": ["koenig_2015"]
        }
      ],
      "clinicalImplications": "May require dose adjustment or additional monitoring; genetic testing may be beneficial",
      "drugInteractions": {
        "methadone": {
          "mechanism": "Inhibits CYP2D6 enzyme",
          "consequence": "Impaired ibogaine metabolism",
          "riskLevel": "critical",
          "contraindicationType": "absolute_if_current_use"
        }
      }
    },
    {
      "id": "rf_ibogaine_opioid_use_001",
      "name": "Current Opioid Use",
      "category": "behavioral",
      "subcategory": "substance_use",
      "description": "Active use of opioids, especially long-acting",
      "severity": "critical",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "absolute_for_long_acting",
          "riskLevel": "critical",
          "specificOpioids": [
            {
              "opioid": "methadone",
              "severity": "critical",
              "contraindicationType": "absolute",
              "mechanisms": [
                "Inhibits CYP2D6, impairing ibogaine metabolism",
                "Dangerous drug interaction",
                "Overdose risk"
              ],
              "requirement": "Complete withdrawal before ibogaine administration"
            },
            {
              "opioid": "long_acting_opioids",
              "severity": "critical",
              "examples": ["buprenorphine", "extended_release_formulations"],
              "contraindicationType": "absolute",
              "requirement": "Complete withdrawal before administration"
            }
          ],
          "shortActingOpioids": {
            "riskLevel": "moderate_to_high",
            "requirement": "Appropriate washout period before ibogaine"
          },
          "consequences": [
            "Potentially fatal drug interactions",
            "Increased overdose risk",
            "Unpredictable effects"
          ],
          "citations": ["cherian_2024"],
          "evidenceQuality": "strong"
        }
      ],
      "fatalityData": {
        "multipleAddictions": "Some fatality cases involved concurrent addiction to cocaine, alcohol, methamphetamine, and heroin",
        "citation": "cherian_2024"
      }
    },
    {
      "id": "rf_ibogaine_polydrug_complex_001",
      "name": "Polydrug Use Patterns",
      "category": "behavioral",
      "subcategory": "substance_use",
      "description": "Use of multiple substances with ibogaine",
      "severity": "high_to_critical",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "riskLevel": "high_to_critical",
          "dangerousCombinations": [
            {
              "substances": ["ibogaine", "stimulants"],
              "examples": ["cocaine", "methamphetamine"],
              "riskLevel": "high",
              "consequences": ["Increased cardiovascular burden", "Unpredictable interactions"]
            },
            {
              "substances": ["ibogaine", "alcohol"],
              "riskLevel": "high",
              "consequences": ["Increased adverse event risk", "Liver burden"]
            },
            {
              "substances": ["ibogaine", "qt_prolonging_drugs"],
              "riskLevel": "critical",
              "mechanism": "Additive QT prolongation",
              "consequence": "Severe arrhythmia risk",
              "contraindicationType": "absolute"
            }
          ],
          "fatalityCases": {
            "description": "Some deaths involved individuals addicted to multiple drugs",
            "substances": ["cocaine", "alcohol", "methamphetamine", "heroin"],
            "citation": "cherian_2024"
          },
          "citations": ["cherian_2024", "bremler_2023", "rocha_2023", "koenig_2015"]
        }
      ],
      "harmReductionStrategies": [
        "Complete substance use history",
        "Appropriate washout periods",
        "Avoid all contraindicated substances",
        "Medical supervision"
      ]
    },
    {
      "id": "rf_ibogaine_psychiatric_001",
      "name": "Pre-existing Mental Illness",
      "category": "psychiatric",
      "description": "History of psychosis, bipolar disorder, or other severe mental illness",
      "severity": "high",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "relative",
          "activeState": "absolute",
          "riskLevel": "high",
          "specificConditions": [
            {
              "condition": "psychosis",
              "contraindicationType": "absolute_if_active",
              "relativeIfHistory": true,
              "risks": ["Psychotic episode", "Mania", "Severe psychiatric decompensation"]
            },
            {
              "condition": "bipolar_disorder",
              "contraindicationType": "absolute_if_active",
              "relativeIfHistory": true,
              "risks": ["Manic episode induction", "Severe mood destabilization"]
            }
          ],
          "surveyData": {
            "psychiatricDiagnosisPostUse": {
              "questionnaire": 37.5,
              "interview": 33,
              "unit": "percent",
              "context": "Among those with negative psychological responses lasting 72+ hours",
              "citation": "bremler_2023"
            },
            "anxietyWorseningOrOnset": {
              "questionnaire": 87,
              "interview": 93,
              "unit": "percent",
              "context": "Among those with negative responses",
              "citation": "bremler_2023"
            }
          },
          "requiredPrecautions": [
            "Comprehensive psychiatric screening",
            "Specialist consultation",
            "Extreme caution",
            "Enhanced monitoring",
            "Psychiatric support during and after"
          ],
          "citations": ["cherian_2024", "tabaac_2024", "honk_2024", "rosenblat_2023", "bremler_2023"],
          "evidenceQuality": "moderate"
        }
      ]
    },
    {
      "id": "rf_ibogaine_pregnancy_001",
      "name": "Pregnancy and Breastfeeding",
      "category": "demographic",
      "subcategory": "reproductive",
      "description": "Use during pregnancy or while breastfeeding",
      "severity": "high",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "relative_to_absolute",
          "riskLevel": "high",
          "recommendation": "Generally advisable to avoid",
          "citations": ["white_2024", "izmi_2024"]
        }
      ]
    },
    {
      "id": "rf_ibogaine_uncontrolled_setting_001",
      "name": "Uncontrolled Settings",
      "category": "environmental",
      "description": "Use outside of medical or therapeutic supervision",
      "severity": "critical",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "relative",
          "riskLevel": "critical",
          "specificRisks": [
            "Sudden death without medical intervention",
            "Inability to manage cardiac complications",
            "No monitoring for adverse events",
            "Delayed or absent emergency response"
          ],
          "riskWindow": "Particularly first 72 hours post-administration",
          "requiredSupport": [
            "Medical supervision",
            "ECG monitoring capability",
            "Emergency response capability",
            "Proper screening",
            "Supportive environment"
          ],
          "citations": ["knuijver_2022", "rocha_2023"],
          "evidenceQuality": "strong"
        }
      ],
      "note": "Given ibogaine's cardiac risks, unsupervised use is particularly dangerous"
    },
    {
      "id": "rf_ibogaine_seizure_history_001",
      "name": "History of Seizures",
      "category": "physiological",
      "subcategory": "neurological",
      "description": "Personal history of seizure disorder",
      "severity": "moderate_to_high",
      "substanceInteractions": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "relative",
          "riskLevel": "moderate_to_high",
          "specificRisk": "Increased risk of seizure activity",
          "caseReports": {
            "description": "Man developed generalized seizures after taking 38 grams ibogaine for spiritual cleansing (purchased online)",
            "citation": "rocha_2023"
          },
          "citations": ["rocha_2023"]
        }
      ]
    }
  ],

  "medicalConditions": [
    {
      "id": "cond_ibogaine_cardiovascular_001",
      "name": "Cardiovascular Conditions (Ibogaine-Specific)",
      "category": "cardiovascular",
      "icd10": ["I00-I99"],
      "description": "Various heart and vascular conditions - ABSOLUTE contraindication for ibogaine",
      "severity": "critical",
      "subtypes": [
        {
          "condition": "Long QT Syndrome",
          "icd10": "I45.81",
          "contraindicationType": "absolute",
          "mechanism": "Ibogaine further prolongs QT interval",
          "consequence": "Fatal arrhythmias"
        },
        {
          "condition": "Cardiac Arrhythmias",
          "contraindicationType": "absolute",
          "consequence": "Exacerbation, potentially fatal outcomes"
        },
        {
          "condition": "Coronary Artery Disease",
          "contraindicationType": "absolute_if_severe",
          "relativeIfControlled": "requires_extreme_caution"
        }
      ],
      "substanceRisks": [
        {
          "substanceId": "ibogaine_001",
          "contraindicationType": "absolute",
          "specificRisks": [
            {
              "risk": "sudden_cardiac_death",
              "mechanism": "QT prolongation leading to Torsade de pointes",
              "prevalence": "6 of 19 reviewed fatalities had pre-existing heart conditions",
              "severity": "fatal"
            },
            {
              "risk": "severe_arrhythmia",
              "timeframe": "Within 72 hours of administration",
              "severity": "critical"
            }
          ],
          "requiredPrecautions": [
            "Absolute exclusion if uncontrolled",
            "If any cardiac history: extensive evaluation",
            "Continuous cardiac monitoring",
            "Immediate access to emergency cardiac care"
          ],
          "citations": ["cherian_2024", "koenig_2015", "glue_2016", "rocha_2023", "baumeister_2015"]
        }
      ],
      "prevalence": "Variable by specific condition and age"
    }
  ],

  "contraindications": {
    "absolute": [
      {
        "id": "contra_ibogaine_absolute_001",
        "condition": "Pre-existing heart conditions",
        "description": "Cardiac arrhythmias, long QT syndrome, or other significant cardiovascular conditions",
        "severity": "critical",
        "rationale": "High risk of fatal arrhythmias",
        "citations": ["cherian_2024", "fonzo_2025", "koenig_2015"]
      },
      {
        "id": "contra_ibogaine_absolute_002",
        "condition": "Prolonged baseline QT interval",
        "severity": "critical",
        "rationale": "Ibogaine further prolongs QT, risking fatal arrhythmias",
        "citations": ["koenig_2015"]
      },
      {
        "id": "contra_ibogaine_absolute_003",
        "condition": "Concurrent use of QT-prolonging medications",
        "severity": "critical",
        "rationale": "Additive QT prolongation",
        "examples": ["Certain antibiotics", "Antipsychotics", "Antiarrhythmics"],
        "citations": ["koenig_2015"]
      },
      {
        "id": "contra_ibogaine_absolute_004",
        "condition": "Severe electrolyte imbalances",
        "specificImbalances": ["Uncorrected hypokalemia", "Uncorrected hypomagnesemia"],
        "severity": "critical",
        "rationale": "Increases cardiac risk",
        "requirement": "Must be corrected before administration",
        "citations": ["koenig_2015"]
      },
      {
        "id": "contra_ibogaine_absolute_005",
        "condition": "Current use of long-acting opioids",
        "specificSubstances": ["Methadone", "Buprenorphine"],
        "severity": "critical",
        "rationale": "Fatal drug interactions",
        "requirement": "Complete withdrawal required before ibogaine",
        "citations": ["cherian_2024"]
      }
    ],
    "relative": [
      {
        "id": "contra_ibogaine_relative_001",
        "condition": "History of mental illness",
        "specificConditions": ["Psychosis", "Bipolar disorder", "Severe depression"],
        "severity": "high",
        "rationale": "Risk of psychiatric decompensation",
        "requirements": [
          "Comprehensive psychiatric evaluation",
          "Risk-benefit assessment",
          "Enhanced monitoring",
          "Psychiatric support available"
        ],
        "citations": ["cherian_2024", "tabaac_2024", "honk_2024", "rosenblat_2023"]
      },
      {
        "id": "contra_ibogaine_relative_002",
        "condition": "Pregnancy and breastfeeding",
        "severity": "high",
        "recommendation": "Generally advisable to avoid",
        "citations": ["white_2024", "izmi_2024"]
      },
      {
        "id": "contra_ibogaine_relative_003",
        "condition": "Poly-substance use",
        "severity": "high",
        "specificConcerns": ["Stimulants", "Alcohol"],
        "rationale": "Increased adverse event risk due to drug interactions",
        "citations": ["cherian_2024", "bremler_2023"]
      },
      {
        "id": "contra_ibogaine_relative_004",
        "condition": "Use in uncontrolled settings",
        "severity": "critical",
        "rationale": "Lack of medical supervision, monitoring, and emergency response",
        "requirement": "Should only be used in controlled medical settings",
        "citations": ["knuijver_2022", "rocha_2023"]
      },
      {
        "id": "contra_ibogaine_relative_005",
        "condition": "Moderate cardiovascular disease",
        "severity": "high",
        "requirement": "Extreme caution and close medical supervision",
        "citations": ["koenig_2015"]
      },
      {
        "id": "contra_ibogaine_relative_006",
        "condition": "History of seizures",
        "severity": "moderate_to_high",
        "rationale": "Increased risk of seizure activity",
        "citations": ["rocha_2023"]
      }
    ]
  },

  "adverseEvents": [
    {
      "id": "ae_ibogaine_nausea_001",
      "name": "Gastrointestinal Distress",
      "category": "physiological",
      "subcategory": "gastrointestinal",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Nausea, vomiting, and diarrhea",
      "prevalence": {
        "nausea_vomiting": {
          "value": 62,
          "unit": "percent",
          "context": "Most common acute adverse effect",
          "specificContext": "In ayahuasca users (containing ibogaine)",
          "citation": "bouso_2022"
        },
        "status": "Most common acute adverse effect of ibogaine"
      },
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "symptoms": ["Nausea", "Vomiting", "Diarrhea"],
          "onset": "Early in experience",
          "duration": "Hours",
          "management": [
            "Antiemetics may be considered",
            "Hydration",
            "Supportive care"
          ],
          "citations": ["rocha_2023", "ables_2024", "andersen_2021", "bender_2022", "griffin_2024"]
        }
      ],
      "clinicalSignificance": "Usually manageable but can be distressing"
    },
    {
      "id": "ae_ibogaine_qt_prolongation_001",
      "name": "QT Interval Prolongation",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "timeframe": "acute",
      "severity": "critical",
      "description": "Prolongation of QT interval on ECG",
      "mechanism": "Direct cardiac effect of ibogaine",
      "clinicalSignificance": "Can lead to life-threatening arrhythmias",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": {
            "averageIncrease": {
              "value": 95,
              "unit": "milliseconds",
              "range": {"min": 29, "max": 146}
            },
            "clinicallySignificantThreshold": {
              "value": 500,
              "unit": "milliseconds",
              "description": "QTc >500ms considered dangerous"
            },
            "percentageAboveThreshold": {
              "value": 50,
              "unit": "percent",
              "context": "Of participants reached QTc >500ms during observation",
              "citation": "knuijver_2022"
            }
          },
          "timeframe": "During and up to 72 hours post-administration",
          "consequence": "Torsade de pointes arrhythmia (potentially fatal)",
          "metaboliteEffect": {
            "metabolite": "noribogaine",
            "effect": "Also exhibits concentration-dependent QTcI increase",
            "citation": "glue_2016"
          },
          "requiredMonitoring": [
            "Continuous ECG monitoring",
            "Medical supervision",
            "Emergency cardiac intervention capability"
          ],
          "citations": ["rocha_2023", "koenig_2015", "knuijver_2022", "glue_2016"]
        }
      ],
      "riskFactors": [
        "Pre-existing QT prolongation",
        "Electrolyte imbalances",
        "Concurrent QT-prolonging medications",
        "Genetic factors (hERG mutations)"
      ]
    },
    {
      "id": "ae_ibogaine_bradycardia_001",
      "name": "Bradycardia",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "timeframe": "acute",
      "severity": "moderate_to_critical",
      "description": "Abnormally slow heart rate",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "mechanism": "Direct cardiac effect",
          "timeframe": "Within first 72 hours",
          "clinicalSignificance": "Associated with sudden death risk",
          "requiredMonitoring": "Continuous cardiac monitoring",
          "citations": ["rocha_2023"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_hypertension_001",
      "name": "Hypertension",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "timeframe": "acute",
      "severity": "moderate_to_high",
      "description": "Elevated blood pressure",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": "Some individuals develop systolic BP >160 mmHg and diastolic >100 mmHg",
          "riskFactors": ["Older patients", "Underlying medical conditions"],
          "citations": ["bender_2022"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_ataxia_001",
      "name": "Ataxia",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute",
      "severity": "moderate",
      "description": "Loss of coordination and balance",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": {
            "value": 100,
            "unit": "percent",
            "context": "All patients in opioid use disorder detoxification study",
            "citation": "knuijver_2022"
          },
          "duration": "During and shortly after effects",
          "functionalImpact": "Difficulty with movement and balance",
          "management": "Ensure safe environment, prevent falls",
          "citations": ["bender_2022", "rocha_2023", "knuijver_2022"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_seizures_001",
      "name": "Seizures",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute",
      "severity": "high",
      "description": "Convulsive episodes",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": "Documented in case reports",
          "caseExample": {
            "description": "Generalized seizures after 38 grams ibogaine (purchased online)",
            "context": "Taken for spiritual cleansing",
            "citation": "rocha_2023"
          },
          "riskFactors": [
            "Very high doses",
            "History of seizure disorder",
            "Unknown purity/content"
          ],
          "citations": ["rocha_2023"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_neuro_other_001",
      "name": "Other Neurological Effects",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "symptoms": [
            "Tremor",
            "Dizziness",
            "Agitation"
          ],
          "citations": ["bender_2022", "ables_2024"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_anxiety_001",
      "name": "Acute Anxiety",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "description": "Transient anxiety during experience",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": "Frequently reported",
          "characteristics": "Transient",
          "citations": ["andersen_2021"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_confusion_001",
      "name": "Confusion and Disorientation",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "symptoms": [
            "Confusion",
            "Disorientation",
            "Agitation",
            "Derealization"
          ],
          "prevalence": "Reported in several studies",
          "citations": ["rocha_2023", "ables_2024", "rossi_2023", "ona_2022"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_perceptual_001",
      "name": "Perceptual Changes",
      "category": "psychological",
      "subcategory": "perceptual",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "description": "Altered perceptions during experience",
          "citations": ["rocha_2023"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_autonomic_001",
      "name": "Autonomic Effects",
      "category": "physiological",
      "subcategory": "autonomic",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "symptoms": [
            "Feeling cold",
            "Motor agitation/restlessness",
            "Hyperhidrosis (excessive sweating)",
            "Urinary incontinence",
            "Orthostatic hypotension (low blood pressure upon standing)"
          ],
          "citations": ["rocha_2023"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_persistent_psych_001",
      "name": "Persistent Psychological Effects",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "variable",
      "description": "Long-term psychological effects following ibogaine use",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": "Small percentage may experience",
          "specificEffects": [
            "Anxiety",
            "Depression",
            "Persistent perceptual disturbances (HPPD)"
          ],
          "riskFactors": [
            "Pre-existing mental health conditions",
            "Challenging or traumatic experiences during session"
          ],
          "traumaReexperiencing": {
            "prevalence": {
              "ptsd": 37.5,
              "unit": "percent",
              "context": "Of those with self-reported PTSD in ayahuasca study",
              "citation": "weiss_2023"
            }
          },
          "generalPopulation": {
            "functionalImpairment": {
              "value": 8.9,
              "unit": "percent",
              "context": "Lifetime classic psychedelic users",
              "citation": "ghaznavi_2025"
            },
            "soughtHelp": {
              "value": 2.6,
              "unit": "percent",
              "context": "Sought medical/psychiatric/psychological assistance",
              "citation": "ghaznavi_2025"
            }
          },
          "citations": ["weiss_2023", "ghaznavi_2025"]
        }
      ],
      "support": [
        "Integration therapy",
        "Psychiatric follow-up",
        "Trauma-informed care if needed"
      ]
    },
    {
      "id": "ae_ibogaine_hppd_001",
      "name": "Hallucinogen Persisting Perception Disorder (HPPD)",
      "category": "perceptual",
      "timeframe": "long_term",
      "severity": "variable",
      "description": "Persistent perceptual disturbances after ibogaine",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "prevalence": "Unknown; documented cases exist",
          "symptoms": [
            "Visual disturbances",
            "Geometric patterns",
            "Halos",
            "Trails"
          ],
          "note": "Less studied than HPPD from classical psychedelics",
          "citations": ["knuijver_2018"]
        }
      ]
    },
    {
      "id": "ae_ibogaine_sudden_death_001",
      "name": "Sudden Death",
      "category": "physiological",
      "subcategory": "fatal",
      "timeframe": "acute",
      "severity": "fatal",
      "description": "Cardiac arrest and death",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "mechanism": [
            "Bradycardia",
            "QT prolongation leading to Torsade de pointes",
            "Cardiac arrhythmias"
          ],
          "timeframe": "Particularly within first 72 hours",
          "prevalenceData": {
            "fatalitiesReviewed": 19,
            "withPreexistingHeartConditions": 6
          },
          "riskFactors": [
            "Pre-existing cardiovascular conditions",
            "Electrolyte imbalances",
            "Polydrug use",
            "Lack of medical monitoring",
            "Uncontrolled settings"
          ],
          "prevention": [
            "Comprehensive cardiovascular screening",
            "Continuous cardiac monitoring",
            "Medical supervision",
            "Electrolyte management",
            "Emergency response capability"
          ],
          "citations": ["rocha_2023", "cherian_2024", "koenig_2015"]
        }
      ],
      "clinicalSignificance": "Ibogaine has unique fatality risk not seen with classical psychedelics"
    }
  ],

  "contaminationQualityFactors": [
    {
      "id": "contam_ibogaine_purity_001",
      "name": "Variable Purity and Potency",
      "category": "quality",
      "severity": "high",
      "description": "Wide variation in ibogaine content across preparations",
      "substanceExamples": [
        {
          "substance": "ibogaine_extract",
          "purityRange": {"min": 8.2, "max": 32.9, "unit": "percent"},
          "consequence": "Difficult to determine accurate dosing",
          "risk": "Accidental overdose or underdosing",
          "citation": "rocha_2023"
        },
        {
          "substance": "ibogaine_hydrochloride",
          "purityRange": {"min": 61.5, "max": 73.4, "unit": "percent"},
          "consequence": "More consistent but still variable",
          "citation": "rocha_2023"
        }
      ],
      "specificRisks": [
        "Unknown potency makes dosing dangerous",
        "Overdose risk with high-purity samples",
        "Sub-therapeutic effects with low-purity samples"
      ],
      "caseExample": {
        "description": "Some samples found to contain no ibogaine or unidentified substances",
        "citation": "rocha_2023"
      },
      "harmReduction": [
        "Purchase from reputable sources with quality control",
        "Laboratory testing when possible",
        "Start with lower doses",
        "Medical supervision"
      ]
    },
    {
      "id": "contam_ibogaine_adulterants_001",
      "name": "Adulteration and Unknown Contents",
      "category": "contamination",
      "severity": "high_to_critical",
      "description": "Presence of unknown substances or complete absence of ibogaine",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "findings": [
            "Some samples contained no ibogaine",
            "Unidentified substances present",
            "Variable composition"
          ],
          "source": "Unregulated markets, online purchases",
          "consequences": [
            "Unpredictable effects",
            "Toxicity from unknown substances",
            "Complete ineffectiveness"
          ],
          "citations": ["rocha_2023"]
        }
      ],
      "harmReduction": [
        "Avoid online purchases without verification",
        "Use regulated pharmaceutical-grade when possible",
        "Laboratory testing",
        "Trusted suppliers with quality control"
      ]
    },
    {
      "id": "contam_ibogaine_storage_001",
      "name": "Processing and Storage Issues",
      "category": "quality",
      "severity": "moderate",
      "description": "Impurities from processing or storage",
      "substanceOccurrence": [
        {
          "substanceId": "ibogaine_001",
          "issue": "Impurities introduced during processing or storage",
          "consequence": "Can contribute to adverse events",
          "citations": ["alper_2008"]
        }
      ]
    }
  ],

  "harmReductionStrategies": [
    {
      "id": "harm_ibogaine_screening_001",
      "name": "Comprehensive Medical Screening",
      "category": "preparation",
      "priority": "critical",
      "description": "Extensive pre-use medical evaluation",
      "components": [
        {
          "component": "cardiovascular_screening",
          "requirements": [
            "Baseline ECG mandatory",
            "Cardiac history assessment",
            "Evaluation for QT-prolonging medications",
            "Assessment for structural heart disease"
          ]
        },
        {
          "component": "electrolyte_panel",
          "requirements": [
            "Potassium levels",
            "Magnesium levels",
            "Correction of any imbalances before administration"
          ]
        },
        {
          "component": "medication_review",
          "requirements": [
            "Complete list of all medications",
            "Identification of contraindicated drugs",
            "Appropriate washout periods for opioids",
            "Discontinuation of QT-prolonging medications"
          ]
        },
        {
          "component": "psychiatric_screening",
          "requirements": [
            "Mental health history",
            "Current psychiatric status",
            "Risk assessment for psychotic disorders"
          ]
        },
        {
          "component": "substance_use_history",
          "requirements": [
            "Current substance use",
            "Opioid use patterns",
            "Polydrug use assessment",
            "Appropriate cessation timelines"
          ]
        }
      ],
      "absoluteRequirement": true,
      "citations": ["cherian_2024", "koenig_2015", "rocha_2023"]
    },
    {
      "id": "harm_ibogaine_monitoring_001",
      "name": "Continuous Medical Monitoring",
      "category": "session_management",
      "priority": "critical",
      "description": "Real-time physiological monitoring during and after administration",
      "requirements": [
        {
          "parameter": "ecg_monitoring",
          "type": "continuous",
          "duration": "During session and 72 hours post",
          "purpose": "Detect QT prolongation and arrhythmias",
          "critical": true
        },
        {
          "parameter": "vital_signs",
          "measurements": ["Heart rate", "Blood pressure", "Temperature", "Respiratory rate"],
          "frequency": "Continuous or very frequent",
          "duration": "Throughout session"
        },
        {
          "parameter": "medical_supervision",
          "requirements": [
            "Physician or qualified medical professional present",
            "Emergency medical equipment available",
            "Ability to manage cardiac emergencies"
          ]
        }
      ],
      "environment": "Medical facility or appropriately equipped setting",
      "citations": ["glue_2016", "koenig_2015", "knuijver_2022"]
    },
    {
      "id": "harm_ibogaine_dosing_001",
      "name": "Careful Dosing",
      "category": "substance_preparation",
      "priority": "high",
      "strategies": [
        {
          "strategy": "weight_based_dosing",
          "description": "Calculate dose based on body weight",
          "typicalRange": {"min": 25, "max": 42, "unit": "mg/kg"},
          "note": "Medical supervision required"
        },
        {
          "strategy": "pharmaceutical_grade",
          "description": "Use pharmaceutical-grade ibogaine hydrochloride when possible",
          "rationale": "More consistent purity (61.5-73.4%) than extracts (8.2-32.9%)"
        },
        {
          "strategy": "avoid_unknown_sources",
          "description": "Never use ibogaine from unknown or unverified sources",
          "rationale": "High risk of adulteration or absence of active compound"
        }
      ],
      "citations": ["gomez-escolar_2024", "rocha_2023"]
    },
    {
      "id": "harm_ibogaine_setting_001",
      "name": "Controlled Medical Setting",
      "category": "setting",
      "priority": "critical",
      "description": "Ibogaine should only be administered in appropriate medical settings",
      "requirements": [
        "Medical facility or clinical setting",
        "Emergency medical equipment",
        "Cardiac monitoring capability",
        "Resuscitation equipment",
        "Trained medical staff",
        "24-hour monitoring capability"
      ],
      "rationale": "Cardiac risks require immediate medical intervention capability",
      "uncontrolledSettings": {
        "risk": "Critical - potentially fatal",
        "recommendation": "Strongly contraindicated"
      },
      "citations": ["knuijver_2022", "rocha_2023"]
    },
    {
      "id": "harm_ibogaine_integration_001",
      "name": "Integration Support",
      "category": "post_session",
      "priority": "high",
      "description": "Post-session support for processing experience",
      "components": [
        "Psychological support",
        "Integration therapy",
        "Follow-up medical monitoring",
        "Psychiatric support if needed"
      ],
      "duration": "Weeks to months post-experience",
      "specialConsiderations": [
        "May be particularly important for those using for addiction treatment",
        "Address any psychological distress",
        "Support behavioral changes"
      ]
    },
    {
      "id": "harm_ibogaine_education_001",
      "name": "Education and Informed Consent",
      "category": "preparation",
      "priority": "high",
      "description": "Comprehensive education about ibogaine risks",
      "topics": [
        "Cardiac risks including sudden death",
        "QT prolongation and arrhythmias",
        "Importance of medical screening",
        "Necessity of medical monitoring",
        "Drug interactions, especially opioids",
        "Psychiatric risks",
        "What to expect during experience",
        "Requirement for controlled medical setting"
      ],
      "format": [
        "Verbal education",
        "Written materials",
        "Opportunity for questions",
        "Documented informed consent"
      ],
      "emphasis": "Unique and serious cardiac risks"
    }
  ],

  "emergencyResponseProtocols": [
    {
      "id": "emergency_ibogaine_cardiac_001",
      "name": "Cardiac Emergency Response",
      "category": "medical_emergency",
      "priority": "critical",
      "applicableEvents": [
        "Severe QT prolongation (>500ms)",
        "Torsade de pointes",
        "Cardiac arrhythmias",
        "Bradycardia with hemodynamic compromise",
        "Cardiac arrest"
      ],
      "immediateActions": [
        {
          "action": "continuous_ecg_monitoring",
          "note": "Should already be in place"
        },
        {
          "action": "activate_emergency_response",
          "note": "Call code team if in hospital"
        },
        {
          "action": "ensure_airway_breathing_circulation",
          "note": "Basic life support principles"
        },
        {
          "action": "check_electrolytes",
          "specificChecks": ["Potassium", "Magnesium", "Calcium"],
          "correction": "Correct any abnormalities immediately"
        }
      ],
      "medications": [
        {
          "medication": "magnesium_sulfate",
          "indication": "Torsade de pointes",
          "dosing": "Per ACLS protocols",
          "priority": "first_line"
        },
        {
          "medication": "isoproterenol",
          "indication": "Bradycardia, Torsade de pointes",
          "note": "May be needed for rate support"
        },
        {
          "medication": "atropine",
          "indication": "Symptomatic bradycardia",
          "note": "Per ACLS protocols"
        }
      ],
      "equipment": [
        "Defibrillator/AED",
        "Pacing capability (transcutaneous or transvenous)",
        "Advanced airway equipment",
        "Emergency medications"
      ],
      "prevention": "This is why continuous cardiac monitoring and medical setting are mandatory"
    },
    {
      "id": "emergency_ibogaine_seizure_001",
      "name": "Seizure Management",
      "category": "medical_emergency",
      "priority": "high",
      "immediateActions": [
        {
          "action": "protect_from_injury",
          "details": ["Remove dangerous objects", "Position safely", "Do not restrain"]
        },
        {
          "action": "maintain_airway",
          "note": "Position to prevent aspiration"
        },
        {
          "action": "time_seizure",
          "note": "Duration important for treatment decisions"
        },
        {
          "action": "monitor_vital_signs",
          "note": "Especially oxygen saturation"
        }
      ],
      "medications": [
        {
          "medication": "benzodiazepines",
          "specific": ["lorazepam", "diazepam"],
          "indication": "Prolonged seizure (>5 minutes) or status epilepticus",
          "priority": "first_line"
        }
      ],
      "postSeizure": [
        "Recovery position",
        "Monitor consciousness",
        "Assess for injuries",
        "Medical evaluation"
      ]
    },
    {
      "id": "emergency_ibogaine_psychological_001",
      "name": "Acute Psychological Distress Management",
      "category": "psychological_support",
      "priority": "moderate_to_high",
      "firstLine": [
        {
          "intervention": "reassurance",
          "description": "Calm, supportive presence"
        },
        {
          "intervention": "environmental_adjustment",
          "actions": ["Quiet space", "Reduce stimulation"]
        },
        {
          "intervention": "grounding_techniques",
          "examples": ["Breathing exercises", "Physical grounding"]
        }
      ],
      "pharmacological": [
        {
          "medication": "benzodiazepines",
          "indication": "If non-pharmacological approaches insufficient",
          "caution": "Be mindful of cardiovascular status"
        }
      ],
      "note": "Psychological distress during ibogaine sessions should be managed carefully due to cardiac monitoring requirements"
    }
  ],

  "clinicalConsiderations": [
    {
      "id": "clinical_ibogaine_unique_001",
      "name": "Unique Risk Profile",
      "description": "Ibogaine has a unique risk profile distinct from classical psychedelics",
      "keyPoints": [
        "Not a classical serotonergic psychedelic",
        "Significant cardiovascular risks including sudden death",
        "QT prolongation is near-universal and can be severe",
        "Requires medical monitoring not necessary for substances like psilocybin or LSD",
        "Cannot be safely used in recreational or unsupervised settings",
        "Cardiac screening is mandatory, not optional"
      ],
      "implication": "Ibogaine requires a higher standard of medical care than other psychedelics"
    },
    {
      "id": "clinical_ibogaine_addiction_001",
      "name": "Addiction Treatment Context",
      "description": "Ibogaine is often used for addiction treatment, particularly opioid use disorder",
      "considerations": [
        "Paradoxical contraindication: opioid users are target population but current opioid use is dangerous",
        "Requires complete opioid withdrawal before administration",
        "Methadone poses particular risk due to CYP2D6 inhibition",
        "Complex medical management needed",
        "High-risk population may have other health complications"
      ],
      "citations": ["cherian_2024", "knuijver_2022"]
    },
    {
      "id": "clinical_ibogaine_regulation_001",
      "name": "Regulatory Status",
      "description": "Ibogaine regulatory status varies globally",
      "status": {
        "unscheduled": ["Many countries including Canada, Mexico"],
        "scheduled": ["United States (Schedule I)", "Some European countries"],
        "note": "Legal status affects access to medical settings and quality control"
      },
      "implication": "Users may travel internationally for treatment, complicating follow-up care"
    },
    {
      "id": "clinical_ibogaine_research_gaps_001",
      "name": "Research Gaps",
      "description": "Significant gaps in ibogaine research",
      "gaps": [
        "Limited large-scale clinical trials",
        "Few long-term outcome studies",
        "Unclear prevalence of adverse events in uncontrolled settings",
        "Optimal dosing not well established",
        "Genetic screening protocols not standardized",
        "Long-term cardiac effects unknown"
      ],
      "implication": "Risk-benefit profile less well characterized than classical psychedelics"
    }
  ],

  "specialPopulations": [
    {
      "id": "pop_ibogaine_addiction_001",
      "name": "Individuals with Substance Use Disorders",
      "description": "Primary population seeking ibogaine treatment",
      "specificConsiderations": [
        "Often have complex medical histories",
        "May have cardiovascular complications from drug use",
        "Polydrug use common",
        "Nutritional deficiencies possible",
        "Electrolyte imbalances more common",
        "Hepatic impairment possible",
        "Higher baseline medical risk"
      ],
      "requiredPrecautions": [
        "Comprehensive medical workup",
        "Complete substance use history",
        "Appropriate cessation/withdrawal protocols",
        "Enhanced medical monitoring",
        "Nutritional support",
        "Electrolyte correction"
      ]
    },
    {
      "id": "pop_ibogaine_indigenous_001",
      "name": "Indigenous and Traditional Users",
      "description": "Bwiti and other traditional practitioners",
      "context": {
        "traditionalUse": "Spiritual and healing ceremonies in West Central Africa",
        "preparation": "Often whole plant preparations rather than extracted ibogaine",
        "culturalFramework": "Embedded in spiritual and cultural practices"
      },
      "considerations": [
        "Respect for traditional knowledge and practices",
        "Potential exploitation concerns",
        "Sustainability of iboga plant",
        "Different risk profile in traditional vs. clinical contexts"
      ],
      "ethicalConcerns": [
        "Cultural appropriation",
        "Benefit-sharing",
        "Intellectual property",
        "Environmental sustainability"
      ],
      "citations": ["cherian_2024"]
    }
  ],

  "researchNeeds": [
    {
      "priority": "high",
      "topic": "Cardiac safety protocols",
      "description": "Optimize screening and monitoring to reduce cardiac risks"
    },
    {
      "priority": "high",
      "topic": "Pharmacogenetic screening",
      "description": "Develop standardized genetic testing for CYP2D6 and hERG variants"
    },
    {
      "priority": "high",
      "topic": "Dose optimization",
      "description": "Determine optimal dosing for efficacy while minimizing risks"
    },
    {
      "priority": "high",
      "topic": "Long-term outcomes",
      "description": "Study long-term cardiac and psychological effects"
    },
    {
      "priority": "moderate",
      "topic": "Drug interactions",
      "description": "Comprehensive mapping of dangerous interactions"
    },
    {
      "priority": "moderate",
      "topic": "Alternative formulations",
      "description": "Develop safer analogs or formulations with reduced cardiac risk"
    },
    {
      "priority": "moderate",
      "topic": "Standardized adverse event reporting",
      "description": "Create consistent reporting frameworks for ibogaine-related events"
    }
  ],

  "metadata": {
    "documentSource": "Psychedelic Safety Institute Literature Review - Iboga/Ibogaine Section",
    "substanceFocus": "Ibogaine/Iboga",
    "primaryDifference": "Not a classical psychedelic; unique cardiac risk profile",
    "criticalWarning": "Ibogaine has significant cardiovascular risks including sudden death and requires medical monitoring",
    "geographicScope": "Global with emphasis on West Central Africa (traditional use) and Western clinical contexts",
    "lastLiteratureSearch": "2024",
    "qualityAssessment": "Moderate - less research than classical psychedelics",
    "knownLimitations": [
      "Limited large-scale clinical trials",
      "Many fatality reports but unclear denominator",
      "Variable quality of case reports",
      "Unregulated use contexts poorly documented",
      "Long-term effects understudied"
    ],
    "uniqueConsiderations": [
      "Cardiac monitoring mandatory",
      "Cannot be used in recreational settings",
      "Requires higher level of medical sophistication than other psychedelics",
      "Often used by high-risk populations (addiction)",
      "Legal status complicates access to quality-controlled substance"
    ]
  }
}